Alfuzosin, an alpha-1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH), was developed in the 1980s and approved for medical use in the mid-1990s. Its history is marked by its effectiveness in relieving urinary symptoms associated with BPH, with a generally favorable safety profile. It was approved in the United States in 2003 and is often included in combination therapies for BPH management. Its development included clinical trials that established its efficacy and tolerability, and its widespread use has been supported by post-marketing surveillance programs to monitor safety in real-world populations.
Brand Names
Uroxatral – widely used in the United States, Europe, and other regions
Xatral – commonly used in Europe, Asia, and Latin America
Alfural – available in parts of Asia and Africa
Alfuzosin Sandoz / Alfuzosin Teva – generic formulations under various pharmaceutical companies.
Mechanism of Action
Alfuzosin is a selective alpha-1 adrenergic receptor antagonist that primarily targets the smooth muscle of the prostate, bladder neck, and urethra. By blocking these alpha-1 receptors, alfuzosin causes relaxation of the smooth muscle, reducing urethral resistance and improving urinary flow. This leads to significant relief of lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), such as difficulty in starting urination, weak stream, and incomplete bladder emptying. Unlike some other alpha blockers, alfuzosin is relatively selective for the urinary tract, resulting in minimal impact on blood pressure, and it addresses symptoms without altering the underlying prostate size.
PHARMACOKINETICS
Absorption
Alfuzosin is well absorbed orally, and taking it with food improves its bioavailability and reduces variability. The extended-release formulation reaches peak plasma levels in about 8 hours, allowing for once-daily dosing and steady therapeutic effects.
Distribution
Alfuzosin is widely distributed in the body and is approximately 90% bound to plasma proteins, mainly albumin. It achieves higher concentrations in the prostate and lower urinary tract tissues, which contributes to its targeted effectiveness in relieving BPH symptoms.
Metabolism
Alfuzosin is primarily metabolized in the liver by the cytochrome P450 3A4 (CYP3A4) enzyme. It undergoes extensive first-pass metabolism, producing inactive metabolites. This hepatic metabolism is important for determining drug interactions and dosing considerations, especially in patients with liver impairment.
Elimination
Alfuzosin is mainly excreted in the urine and feces as metabolites, with only a small fraction of the drug excreted unchanged. Its elimination half-life for the extended-release formulation is approximately 10 hours, supporting once-daily dosing. Renal or hepatic impairment can affect clearance, so dose adjustments may be necessary in these patients.
Pharmacodynamics
Alfuzosin works by selectively blocking alpha-1 adrenergic receptors in the smooth muscle of the prostate, bladder neck, and urethra, leading to muscle relaxation. This decreases urethral resistance, improving urinary flow and relieving lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH). Its selectivity for the urinary tract over vascular alpha-1 receptors results in minimal effects on blood pressure, making it generally well-tolerated in patients with BPH.
Administration
Alfuzosin is usually administered orally once daily as an extended-release tablet, preferably immediately after the same meal each day to improve absorption and reduce the risk of dizziness or low blood pressure.
Dosage and Strength
Alfuzosin is typically available in extended-release tablets of 10 mg. The usual recommended dose for adults with BPH is 10 mg once daily, taken after the same meal each day. Dose adjustments are generally not required for mild to moderate renal or hepatic impairment, but caution is advised in severe cases.
Drug Interactions
Alfuzosin is metabolized by CYP3A4, so inhibitors can increase its levels and risk of low blood pressure, while inducers may reduce effectiveness. Combining it with other alpha-1 blockers or antihypertensives can also increase the risk of dizziness or hypotension.
Food Interactions
Alfuzosin should be taken immediately after a meal, as food improves its absorption and helps maintain steady blood levels. Taking it on an empty stomach may reduce effectiveness and increase the risk of dizziness or low blood pressure.
Contraindications
Alfuzosin is contraindicated in patients with hypersensitivity to the drug, severe liver impairment, or those taking strong CYP3A4 inhibitors, as these conditions can lead to dangerously high blood levels and severe low blood pressure. Caution is advised in patients with mild to moderate liver or kidney problems and in those prone to orthostatic hypotension.
Side Effects
Dizziness or lightheadedness, especially when standing up (orthostatic hypotension)
Headache
Fatigue
Nasal congestion
Gastrointestinal effects such as nausea or upset stomach
Toxicity
Alfuzosin has a low toxicity profile at therapeutic doses. Overdose may lead to severe hypotension, dizziness, fainting, or tachycardia. Management of toxicity is primarily supportive, including monitoring vital signs and administering intravenous fluids if needed. There is no specific antidote, and patients should be observed closely until symptoms resolve.
